Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872910 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT01872910 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 124 participants.
The verdict
NCT01872910, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The main purpose of this study is to test if a single dose of LY3023703 relieves pain after wisdom teeth removal. The study will last about one week for each participant, not including screening.
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG LY3023703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01872910
The ClinicalTrials.gov registry entry for NCT01872910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01872910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01872910 about?
NCT01872910 is a clinical study titled "A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal". The main purpose of this study is to test if a single dose of LY3023703 relieves pain after wisdom teeth removal. The study will last about one week for each participant, not including screening.
What is the current status of trial NCT01872910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2013-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01872910?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), LY3023703 (DRUG).
Who is sponsoring clinical trial NCT01872910?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.